PBLA
Panbela Therapeutics, Inc. [PBLA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PBLA Stock Summary
Top 10 Correlated Stocks
PBLA
In the News
PBLA Financial details
Company Rating
Sell
Market Cap
2.86M
Income
-20.75M
Revenue
0
Book val./share
-0.02
Cash/share
0.01
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-0.1
Forward P/E
-
PEG
0.01
P/S
-2.13
P/B
-0.8
P/C
48.95
P/FCF
-0.13
Quick Ratio
0.12
Current Ratio
0.21
Debt / Equity
-1.1
LT Debt / Equity
-0.89
-
-
EPS (TTM)
-259.5
EPS next Y
-
EPS next Q
-
EPS this Y
470.4%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-99.95%
-
-
-
-
SMA20
-16.92%
SMA50
-66.25%
SMA100
-95.21%
Inst Own
0%
Inst Trans
0%
ROA
-179%
ROE
2379%
ROC
-18.44%
Gross Margin
1334%
Oper. Margin
1926%
Profit Margin
1160%
Payout
-9%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.411-477.0
52W High
-
52W Low
-
RSI
31.19
Rel Volume
0.09
Avg Volume
733.11K
Volume
66.29K
Perf Week
-11%
Perf Month
-55.9%
Perf Quarter
-97.1%
Perf Half Y
-97.28%
-
-
-
-
Beta
0.78
-
-
Volatility
0.03%, 0.06%
Prev Close
-5.14%
Price
0.4895
Change
-6.51%
PBLA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -26.1K | -14.8K | -20.77K | -40.75K | -232.43K | |
| Operating cash flow per share | -11.53K | -11.96K | -13.74K | -17.82K | -232.3K | |
| Free cash flow per share | -11.53K | -11.96K | -13.74K | -18.59K | -232.3K | |
| Cash per share | 10.31K | 28K | 24.32K | 1.5K | 23.72K | |
| Book value per share | 5.83K | 26.22K | 20.93K | -9.39K | -43.33K | |
| Tangible book value per share | 5.83K | 26.22K | 20.93K | -9.39K | -43.33K | |
| Share holders equity per share | 5.83K | 26.22K | 20.93K | -9.39K | -43.33K | |
| Interest debt per share | 9.73K | 52.76 | 22.55 | 8.32K | 44.87K | |
| Market cap | 23.94M | 27.53M | 20.26M | 1.5M | 1.99K | |
| Enterprise value | 21.61M | 18.51M | 8.39M | 7.06M | 2.62M | |
| P/E ratio | -3.86 | -5.77 | -2 | -0.04 | 0 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -8.74 | -7.14 | -3.02 | -0.1 | 0 | |
| PFCF ratio | -8.74 | -7.14 | -3.02 | -0.09 | 0 | |
| P/B Ratio | 17.29 | 3.26 | 1.98 | -0.19 | 0 | |
| PTB ratio | 17.29 | 3.26 | 1.98 | -0.19 | 0 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -4.89 | -3.59 | -0.79 | -0.2 | -0.05 | |
| EV to operating cash flow | -7.89 | -4.8 | -1.25 | -0.46 | -0.1 | |
| EV to free cash flow | -7.89 | -4.8 | -1.25 | -0.44 | -0.1 | |
| Earnings yield | -0.26 | -0.17 | -0.5 | -23.26 | -12.7K | |
| Free cash flow yield | -0.11 | -0.14 | -0.33 | -10.61 | -12.69K | |
| Debt to equity | 0.08 | 0 | 0 | -0.85 | -1.1 | |
| Debt to assets | 0.04 | 0 | 0 | 1.37 | 0.44 | |
| Net debt to EBITDA | 0.53 | 1.75 | 1.12 | -0.16 | -0.05 | |
| Current ratio | 1.76 | 7.15 | 4.62 | 0.23 | 0.25 | |
| Interest coverage | -1.97 | -338.47 | -910 | -118.38 | 161.81 | |
| Income quality | 0.44 | 0.81 | 0.66 | 0.44 | 1 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0.04 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 58.52K | 93.43K | 98.91K | 92.78K | 476.05K | |
| ROIC | -2.7 | -0.64 | -0.94 | 28.2 | -105.2 | |
| Return on tangible assets | -1.97 | -0.49 | -0.79 | -7.02 | -2.14 | |
| Graham Net | 4.05K | 24.52K | 19.37K | -13.65K | -126.94K | |
| Working capital | 1.33M | 8.39M | 9.62M | -6.06M | -9.26M | |
| Tangible asset value | 1.39M | 8.45M | 10.21M | -8.05M | -4.71M | |
| Net current asset value | 1.33M | 8.39M | 9.62M | -11.25M | -13.45M | |
| Invested capital | 0.08 | 0 | 0 | -0.85 | -1.1 | |
| Average receivables | 346.5K | 342K | 322K | 185K | 116K | |
| Average payables | 830.5K | 575.5K | 597K | 1.75M | 6.4M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 50.42 | 35.14 | 23.34 | 29.27 | 141.45 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 7.24 | 10.39 | 15.64 | 12.47 | 2.58 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -4.48 | -0.56 | -0.99 | 4.34 | 5.36 | |
| Capex per share | 0 | 0 | 0 | -769.88 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | -1.18K | 0 | 0 | 0 | 0 | |
| Net income per share | -3.41K | -46.64 | -159.09 | -53.74 | -0.03 | |
| Operating cash flow per share | -3.6K | -748.06 | -156.58 | -45.82 | -0.01 | |
| Free cash flow per share | -3.6K | -748.06 | -156.58 | -45.82 | -0.01 | |
| Cash per share | 925.74 | 401.61 | 196.51 | 6.22 | 0.01 | |
| Book value per share | -5.8K | 194.48 | 130.97 | -17.04 | -0.02 | |
| Tangible book value per share | -5.8K | 194.48 | 130.97 | -17.04 | -0.02 | |
| Share holders equity per share | -5.8K | 194.48 | 130.97 | -17.04 | -0.02 | |
| Interest debt per share | 5.06K | 406.29 | 143.57 | 35.15 | 0.02 | |
| Market cap | 2.43M | 3.46M | 1.69M | 3.82M | 4.34B | |
| Enterprise value | 7.99M | 3.42M | -324.41K | 8.11M | 4.34B | |
| P/E ratio | -0.13 | -1.42 | -0.07 | -0.12 | -167.65 | |
| Price to sales ratio | -1.48 | 0 | 0 | 0 | 0 | |
| POCF ratio | -0.49 | -0.35 | -0.29 | -0.57 | -1.41K | |
| PFCF ratio | -0.49 | -0.35 | -0.29 | -0.57 | -1.41K | |
| P/B Ratio | -0.3 | 1.36 | 0.35 | -1.54 | -921.74 | |
| PTB ratio | -0.3 | 1.36 | 0.35 | -1.54 | -921.74 | |
| EV to sales | -4.88 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -1.75 | -0.68 | 0.05 | -0.52 | -676.53 | |
| EV to operating cash flow | -1.6 | -0.35 | 0.06 | -1.21 | -1.41K | |
| EV to free cash flow | -1.6 | -0.35 | 0.06 | -1.21 | -1.41K | |
| Earnings yield | -1.95 | -0.18 | -3.46 | -2.05 | 0 | |
| Free cash flow yield | -2.06 | -2.82 | -3.4 | -1.75 | 0 | |
| Debt to equity | -0.85 | 2.05 | 1.08 | -2.09 | -1.1 | |
| Debt to assets | 1.37 | 0.32 | 0.27 | 0.49 | 0.44 | |
| Net debt to EBITDA | -1.22 | 0.01 | 0.34 | -0.27 | -0.41 | |
| Current ratio | 0.23 | 0.8 | 1.02 | 0.21 | 0.25 | |
| Interest coverage | -28.31 | -47.65 | -83.96 | 221.01 | -97.83 | |
| Income quality | 1.06 | 1.91 | 0.98 | 0.85 | 0.48 | |
| Dividend Yield | 0 | 0.48 | 0 | 0 | 0 | |
| Payout ratio | 0 | -2.72 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | -1.01 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | -2.11 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | -0.14 | 0 | 0 | 0 | 0 | |
| Graham number | 21.09K | 451.77 | 684.69 | 143.53 | 0.11 | |
| ROIC | 4.24 | -0.07 | -0.57 | -5.77 | -14.51 | |
| Return on tangible assets | -0.95 | -0.04 | -0.3 | -0.74 | -0.55 | |
| Graham Net | -8.43K | -665 | -201.81 | -82.95 | -0.06 | |
| Working capital | -6.06M | -1.91M | 254K | -7.03M | -9.26M | |
| Tangible asset value | -8.05M | 2.54M | 4.8M | -2.48M | -4.71M | |
| Net current asset value | -11.25M | -6.11M | -3.94M | -11.23M | -13.45M | |
| Invested capital | -0.85 | 2.05 | 1.08 | -2.09 | -1.1 | |
| Average receivables | 47.5K | 49K | 121K | 174K | 169K | |
| Average payables | 4.13M | 5.1M | 7.89M | 7.53M | 8.28M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | -2.69 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 157.42 | 135.94 | 129.25 | 75.85 | 126.93 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | -33.43 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.57 | 0.66 | 0.7 | 1.19 | 0.71 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.59 | -0.24 | -1.21 | 3.15 | 1.37 | |
| Capex per share | 0.72 | 0 | 0 | 0 | 0 |
PBLA Frequently Asked Questions
What is Panbela Therapeutics, Inc. stock symbol ?
Panbela Therapeutics, Inc. is a US stock , located in Waconia of Mn and trading under the symbol PBLA
What is Panbela Therapeutics, Inc. stock quote today ?
Panbela Therapeutics, Inc. stock price is $0.4895 today.
Is Panbela Therapeutics, Inc. stock public?
Yes, Panbela Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 733.11K
- Market Capitalization 2.86M
- Employee 7
- CEO Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D.
- Headquarters Waconia,MN,US
- IPO Date 2017-01-03
-
Website
https://www.panbela.com 
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
